Clinical Studies of Cyclazocine in the Treatment of Narcotic Addiction
Abstract
Cyclazocine, a long-acting narcotic antagonist, was found to be safe and useful in the treatment of narcotic addicts in a voluntary municipal hospital. Treatment induction in 15 days to a daily maintenance dose of 4.0 mg. was well tolerated. That dosage effectively blocked clinical and EEG effects of challenges with 15 mg. of intravenous heroin, administered in two minutes, for periods greater than 24 hours. Cyclazocine treatment permits "engagement" and continuity of rehabilitation and resocialization efforts, and provides a useful alternative to the methadone maintenance treatment model.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).